|
Symposium
[Free Online Symposium] Advances in Cancer Therapeutics
Speakers:
Thorsten Melcher, RefleXion Medical; Erin Filbert, Apexigen; Pina Cardarelli, GPCR Therapeutics; Seema Kantak, Exelixis; Samuel Blackman, Day One Biopharmaceuticals; Holger Wesche, Harpoon Therapeutics Inc.; Mikayel Nazloyan, PricewaterhouseCoopers; James Trager, Nkarta Therapeutics; Kristin Bedard, Sutro Biopharma; Sarah Bodary, AbCellera; Steve Kelsey, Revolution Medicines; Tian Zhao, OncoNano
Organizers:
Snow Ge, PhD; Toby Freedman, PhD; Wenfeng Xu, PhD; Donald McCarthy, PhD; Betty Chang, PhD; Joe Carlino, PhD; Peter Staehr, MD; Shichang Miao, PhD
Date:
2022-08-17- 08/18/2022
Time:
8:30-12:30 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-08-16
(it will close sooner if the seating cap is reached)
About the Topic
Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event. About the Speakers
- James Trager, CSO, Nkarta Therapeutics
- Kristin Bedard, VP Discovery, Sutro Biopharma
- Pina Cardarelli, CSO, GPCR Therapeutics
- Seema Kantak, SVP, Head of Biologics & Biotherapeutics, Exelixis
- Samuel Blackman, CMO, Day One Biopharmaceuticals
- Erin Filbert, Director of IO, Apexigen
- Steve Kelsey, President, Research and Development, Revolution Medicines
- Thorsten Melcher, CBO, RefleXion Medical
- Mikayel Nazloyan, Partner, PricewaterhouseCoopers
- Sarah Bodary, VP Portfolio Innovation and Partnering, AbCellera
- Holger Wesche, CSO, Harpoon Therapeutics Inc.
- Tian Zhao, VP R&D, OncoNano
August 17th Agenda
|
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
|
8:30-8:45am
|
11:30-11:45am
|
Welcome Remarks
|
|
|
8:45-9:20am
|
11:45-12:20pm
|
Biology-Guided External-Beam Radiotherapy for All Stages of Cancer
|
Thorsten Melcher, PhD, CBO, RefleXion Medical
|
|
9:20-9:55am
|
12:20-12:55pm
|
APX601: a potent TNFR2 antagonist for reversing tumor-mediated immune suppression
|
Erin Filbert, PhD, Director of IO, Apexigen
|
|
9:55-10:30am
|
12:55-1:30pm
|
Targeting GPCRs: CXCR4 and ADRB2 for the Treatment of Cancer
|
Pina Cardarelli, PhD, CSO, GPCR Therapeutics
|
|
10:30-10:45am
|
1:30-1:45pm
|
Break
|
--
|
|
10:45-11:20am
|
1:44-2:20pm
|
Anti-tissue factor ADC. XB002: A novel anti-tissue factor ADC for the treatment of solid tumors
|
Seema Kantak, PhD, SVP, Head of Biologics & Biotherapeutics, Exelixis
|
|
11:20-11:55am
|
2:20-2:55pm
|
Clinical Development of Tovorafenib, a pan-RAF Inhibitor, for Relapsed/Progressive Pediatric Low-Grade Glioma
|
Sam Blackman, MD, PhD, CMO, Day One Biopharmaceutical
|
|
11:55-12:30pm
|
2:55-3:30pm
|
Novel Approaches to Expand the Therapeutic Index of T cell Engagers
|
Holger Wesche, PhD, CSO, Harpoon Therapeutics Inc.
|
|
12:30-12:50pm
|
3:30-3:50pm
|
PANEL DISCUSSION
|
All speakers
|
August 18th Agenda
|
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
|
8:30-8:45am
|
11:30-11:45am
|
Welcome Remarks
|
|
|
8:45-9:20am
|
11:45-12:20pm
|
Financing Trends in Oncology
|
Mikayel Nazloyan, Partner, PricewaterhouseCoopers
|
|
9:20-9:55am
|
12:20-12:55pm
|
Progress in the development of CAR NK cell therapies for cancer
|
James Trager, PhD, CSO, Nkarta, Inc
|
|
9:55-10:30am
|
12:55-1:30pm
|
Complex Biologics for Cancer Treatment: ADCs and Beyond
|
Kristin Bedard, PhD, VP Discovery, Sutro Biopharma
|
|
10:30-10:45am
|
1:30-1:45pm
|
Break
|
--
|
|
10:45-11:20am
|
1:44-2:20pm
|
Business Development trends in the dynamic oncology market
|
Sarah Bodary, PhD, VP Portfolio Innovation and Partnering, AbCellera
|
|
11:20-11:55am
|
2:20-2:55pm
|
Targeting RAS-addicted cancers with tricomplex RAS(ON) inhibitors
|
Steve Kelsey, MD, President, Research and Development, Revolution Medicines
|
|
11:55-12:30pm
|
2:55-3:30pm
|
Tumor specific delivery of therapeutics using a clinically validated ultra pH-sensitive nanoparticle platform
|
Tian Zhao, Ph.D., VP R&D, OncoNano Medicine
|
|
12:30-12:50pm
|
3:30-3:50pm
|
PANEL DISCUSSION
|
All speakers
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
2025-02-13, [Free Online] The Science and Stories of Promising Biotech Startups
|
2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
|
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
|
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
|
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
|
2025-04-22, [Free Online Workshop] Career Transition Workshop: BD/Sales/Marketing at Vendors/Contract Organizations
|
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Aliri Bioanalysis
to the rescue! Pioneers in LCMS & Oligo bioanalysis w/ 30+ years of experience putting dev. programs back on track with quality data & fast timelines.
|
Submit a Text Ad
|